ARTICLE PDF (Українська)


Renal replacement therapy
cardiovascular diseases
diabetes mellitus

How to Cite

Rustamian, S. T., Katerenchuk, I. P., Ovcharenko, L. K., Tsyganenko, I. V., & Talash, V. V. (2024). CARDIOVASCULAR COMPLICATIONS IN PATIENTS ON RENAL REPLACEMENT THERAPY. Clinical and Preventive Medicine, (1), 33-38.


Introduction. A progressive decrease in the rate of glomerular filtration is an independent risk factor for cardiovascular complications, as well as a marker of an unfavorable prognosis of cardiovascular diseases. Cardiovascular complications arising against the background of end-stage renal failure are the main cause of mortality in patients undergoing renal replacement therapy.

The aim of the study was to determine the features and prevalence of cardiovascular complications in patients undergoing renal replacement therapy.

Materials and methods. A retrospective study was conducted of 114 medical records of nephrology patients who were treated in the center of nephrology and dialysis of Poltava Regional Clinical Hospital n.a. M.V. Sklifosovsky. Patients were divided into three groups: two experimental and one control group. The first experimental group consisted of 44 (38.6%) patients who were on RRT by the method of programmed hemodialysis. The second experimental group consisted of 21 (18.4%) patients who were also undergoing RRT, but by the method of peritoneal dialysis. The control group consisted of 49 (43.0%) patients with CKD stages I-II. Analysis of laboratory data of traditional risk factors for cardiovascular complications (lipidogram), as well as non-traditional ones (level of calcium and phosphorus) was carried out. The frequency of cardiovascular complications in patients on renal replacement therapy was studied.

Results. A statistically significant difference was found between the indicators of the atherogenicity index in the groups GD1 with CG1 (р=0.001) and GD2 with CG2 (р=0.031), PD1 and CG1 (р=0.005) and PD2 with CG2 (р=0.027). When analyzing the correlations between indicators of mineral metabolism in the experimental and control groups, it was found that weak and medium inverse correlations were observed in the experimental groups (GD1: -0.4703, GD2: -0.3219, PD1: -0,2146, PD2: -0.2784, respectively), while in the control groups a direct weak correlation was found (CG1 0.1975, CG2 0.2031, respectively). Chronic heart failure was detected in 75.0% of patients in the GD1 group, in 66.6% – in GD2, and in 100.0% of PD1 and PD2 patients. Valve calcification was observed in 35.0%, 29.1%, 33.3%, and 20.0%, respectively.

Conclusions. Studying the features of cardiovascular complications, control of risk factors, which in any case occur in patients on dialysis therapy, is one of the main directions of controlling the underlying disease, reducing the risk of dangerous cardiovascular complications, prolonging life expectancy and its quality.
ARTICLE PDF (Українська)


Kovesdy C. P. (2022). Epidemiology of chronic kidney disease: an update 2022. Kidney international supplements, 12(1), 7–11.

Lee, T., Flythe, J. E., & Allon, M. (2021). Dialysis Care around the World: A Global Perspectives Series. Kidney, 360, 2(4), 604–607.

GBD 2013 Mortality and Causes of Death Collaborators (2015). Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet (London, England), 385(9963), 117–171.

Bright, R. (1836). Cases and observations illustrative of renal disease accompanied with the secretion of albuminous urine. Guy's Hosp Rep., 1, 336.

Quiroga, B., Ortiz, A., Navarro-González, J. F., Santamaría, R., de Sequera, P., & Díez, J. (2022). From cardiorenal syndromes to cardionephrology: a reflection by nephrologists on renocardiac syndromes. Clinical kidney journal, 16(1), 19–29.

Cozzolino, M., Mangano, M., Stucchi, A., Ciceri, P., Conte, F., & Galassi, A. (2018). Cardiovascular disease in dialysis patients. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 33(suppl_3), iii28–iii34.

Sun, J., Axelsson, J., Machowska, A., Heimbürger, O., Bárány, P., Lindholm, B., Lindström, K., Stenvinkel, P., & Qureshi, A. R. (2016). Biomarkers of Cardiovascular Disease and Mortality Risk in Patients with Advanced CKD. Clinical journal of the American Society of Nephrology : CJASN, 11(7), 1163–1172.

Hill, N. R., Fatoba, S. T., Oke, J. L., Hirst, J. A., O'Callaghan, C. A., Lasserson, D. S., & Hobbs, F. D. (2016). Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. PloS one, 11(7), e0158765.

Baaten, C. C. F. M. J., Vondenhoff, S., & Noels, H. (2023). Endothelial Cell Dysfunction and Increased Cardiovascular Risk in Patients With Chronic Kidney Disease. Circulation research, 132(8), 970–992.

Vila Cuenca, M., Hordijk, P. L., & Vervloet, M. G. (2020). Most exposed: the endothelium in chronic kidney disease. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 35(9), 1478–1487.

Vanholder, R., Van Laecke, S., Glorieux, G., Verbeke, F., Castillo-Rodriguez, E., & Ortiz, A. (2018). Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD). Toxins, 10(6), 237.

Kuo, I. Y., & Chapman, A. B. (2019). Polycystins, ADPKD, and Cardiovascular Disease. Kidney international reports, 5(4), 396–406.

Ladányi, E., Salfer, B., Balla, J., Kárpáti, I., Reusz, G., Szabó, L., Andriska, P., Németh, L., Wittmann, I., & Laczy, B. (2023). Deficiencies in the Recognition and Reporting of Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus; A Hungarian Nationwide Analysis. International journal of public health, 68, 1606151.

Vadalà, G., Alaimo, C., Buccheri, G., Di Fazio, L., Di Caccamo, L., Sucato, V., Cipriani, M., & Galassi, A. R. (2023). Screening and Management of Coronary Artery Disease in Kidney Transplant Candidates. Diagnostics (Basel, Switzerland), 13(16), 2709.

Pallazola, V. A., Davis, D. M., Whelton, S. P., Cardoso, R., Latina, J. M., Michos, E. D., Sarkar, S., Blumenthal, R. S., Arnett, D. K., Stone, N. J., & Welty, F. K. (2019). A Clinician's Guide to Healthy Eating for Cardiovascular Disease Prevention. Mayo Clinic proceedings. Innovations, quality & outcomes, 3(3), 251–267.

Cozzolino, M., Galassi, A., Pivari, F., Ciceri, P., & Conte, F. (2017). The Cardiovascular Burden in End-Stage Renal Disease. Contributions to nephrology, 191, 44–57.

Kipourou, K., O'Driscoll, J. M., & Sharma, R. (2022). Valvular Heart Disease in Patients with Chronic Kidney Disease. European cardiology, 17, e02.

Bucharles, S. G. E., Wallbach, K. K. S., Moraes, T. P., & Pecoits-Filho, R. (2019). Hypertension in patients on dialysis: diagnosis, mechanisms, and management. Jornal brasileiro de nefrologia, 41(3), 400–411.

Mallamaci, F., Torino, C., Sarafidis, P., Ekart, R., Loutradis, C., Siamopoulos, K., Del Giudice, A., Aucella, F., Morosetti, M., Raptis, V., Bikos, A., Papagianni, A., Balafa, O., Pappas, E., Tripepi, R., Marino, C., Tripepi, G., Ferro, C., Malyszko, J., Dekker, F. W., … Zoccali, C. (2020). Treatment-resistant hypertension in the hemodialysis population: a 44-h ambulatory blood pressure monitoring-based study. Journal of hypertension, 38(9), 1849–1856.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.